EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> The FDA cleared Transgene to start a phase 1 trial of its personalized immunotherapy TG4050 in ovarian cancer patients. NEC is co-financing the cancer vaccine trial. Release

> UniQure posted updated data on its hemophilia B gene therapy. The data show the high Factor IX activity seen early in the study has been sustained up to six months. Statement

> A phase 2 trial of Modus Therapeutics’ sickle cell disease drug failed to show a meaningful benefit. The setback led Modus to weigh its options for further development of the asset. Release  

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> TreeFrog Therapeutics raised €7 million ($7.8 million). The French startup aims to move one of its cell therapy research programs into humans in 2024. Statement 

> Pfizer nominated a preclinical development candidate under its collaboration with Sosei Heptares, triggering a $3 million milestone payment. The partners are yet to disclose the target of the small molecule. Release  

> Ixaltis completed phase 2 development of its urinary incontinence drug, litoxetine, setting the French biotech up to move into phase 3. Statement  

Suggested Articles

The response rate was lower in the ONCOS-102 arm than the control cohort, but Targovax saw positives elsewhere.

The €13.9 million series B round will fund a phase 1/2 trial of a therapeutic vaccine in patients with non-small cell lung cancer.

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.